However, baseline characteristics show a heterogeneous study population, with still a considerable percentage of patient with a poor prognosis (defined as grade II or III astrocytoma IDH-WT and GBM IDH-WT/M) and tumor location in the right hemisphere. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).